Fedratinib, An Oral, Selective Inhibitor Of Janus Kinase 2 (Jak2), In Patients With Intermediate-2 Or High-Risk Myelofibrosis (Mf): Updated Results From The Randomized, Placebo-Controlled, Phase Iii Jakarta Trial

BACKGROUND: MF is characterized by anemia, splenomegaly, debilitating constitutional symptoms, and shortened survival. Fedratinib is an oral JAK2 inhibitor approved in the United States for treatment (Tx) of adult patients (pts) with intermediate (INT)-2 or high-risk MF. The randomized, placebo (PBO)-controlled, phase III JAKARTA trial evaluated clinical outcomes with fedratinib in pts with JAK-inhibitor-naïve MF. Initial findings from the JAKARTA study have been reported (Pardanani, JAMA Oncol, 2015). JAKARTA data were recently reanalyzed in preparation for regulatory review.